Other languages Organon & Co.

Equities

OGN

US68622V1061

Market Closed - Nyse Other stock markets 01:30:02 02/05/2024 am IST			5-day change	1st Jan Change
18.83 ^USD	+1.18%		+0.64%	+30.58%

29/04	Piper Sandler Raiises Price Target on Organon to $24 From $22, Maintains Overweight Rating	MT
09/04	Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

El estudio clínico comparativo de fase 3 del candidato a biosimilar de Prolia ® y Xgeva ® (denosumab) HLX14 alcanzó los criterios de valoración primarios	09/04
Klinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre Endpunkte	09/04
L'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primaires	09/04
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	08/04
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	20/03
Philips : une nouvelle directrice financière en octobre	28/02
New York attorney general urges stronger safety warning on asthma drug Singulair	24/02
Organon's Hadlima Chosen by VA as Substitute for Humira	20/02
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	20/02
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	20/02
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	15/02
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued	15/02
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02
Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024	15/02
Organon & Co. Provides Earnings Guidance for the Year 2024	15/02
Organon Says Xaciato Vaginal Gel 2% Now Available in the US via Prescription to Treat Bacterial Vaginosis	10/01
Organon?S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older	10/01
Organon Affirms 2023 Revenue Outlook, Sets 2024 Guidance; Shares Jump	08/01
Organon et Lilly concluent un accord de commercialisation en Europe pour deux médicaments contre la migraine	19/12
Organon y Lilly suscriben acuerdo de comercialización para dos medicamentos contra la migraña en Europa	19/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Organon & Co.

Equities

OGN

US68622V1061

Other languages

Filters